Ferdinand F J
Paul-Ehrlich-Institut, Bundesamt für Sera und Impfstoffe, Langen, Fed. Rep. of Germany.
Arzneimittelforschung. 1990 Jan;40(1):106-10.
In designing antiviral drugs and therapeutic schemes some basic considerations should be taken into account: 1. RNA viruses and especially HIV (Human Immunodeficiency Virus) respond to environmental changes with evading mutations, hence, the high degree of variability of these viruses. All drugs interfering with viral functions will presumably give rise to resistant variants. 2. Approaches using cytotoxic peptides may induce adverse immune responses. Vaccines may elicit neutralizing antibodies, cellular cytotoxic responses, or both. The limitations of subunit vaccines or oligopeptides in eliciting cell mediated cytotoxicity in all vaccinees are outlined. Recent developments and the suitability of the SIV mac/rhesus monkey model are reviewed. The importance of adjuvants is indicated.
在设计抗病毒药物和治疗方案时，应考虑一些基本因素：1. RNA病毒，尤其是人类免疫缺陷病毒（HIV）会通过逃避突变来应对环境变化，因此这些病毒具有高度的变异性。所有干扰病毒功能的药物可能都会产生耐药变体。2. 使用细胞毒性肽的方法可能会引发不良免疫反应。疫苗可能会引发中和抗体、细胞毒性反应或两者皆有。概述了亚单位疫苗或寡肽在所有接种者中引发细胞介导的细胞毒性方面的局限性。综述了猴免疫缺陷病毒（SIV）/恒河猴模型的最新进展及其适用性。指出了佐剂的重要性。
